Southern Illinois Healthcare

sih.net

SIH is a nonprofit integrated health network with over 3,000 employees. It is comprised of over twenty facilities, including three inpatient hospitals, two clinics, two physician office buildings, urgent care and dedicated centers that include neuro, cancer, heart, sleep and rehabilitation. We are dedicated to improving the health and well-being of all of the people in the communities we serve.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

ARMATA PHARMACEUTICALS ANNOUNCES CLEARANCE OF IND FOR PROSTHETIC JOINT INFECTIONS

Armata Pharmaceuticals, Inc | August 02, 2022

news image

Armata Pharmaceuticals, Inc. a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration has cleared Armata's Investigational New Drug application for AP-SA02 in prosthetic joint infection. The company is initiating start-up activities for the Phase 1b/2a trial that will explore the safety, tolerability, and pharmacokinetics of intravenous and i...

Read More

Pharmacy Market

VALEMETOSTAT NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR TREATMENT OF PATIENTS WITH ADULT T-CELL LEUKEMIA/LYMPHOMA

Daiichi Sankyo | December 29, 2021

news image

Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma. ATL is a rare and aggressive type of peripheral T-cell lymphoma that occurs with greater frequency in parts of Japan and other regions.1,2 Patients with ATL face a poor prognosi...

Read More

Business Insights

OPTOMED SIGNS AN INDUSTRIAL PARTNERSHIP WITH A FRENCH AI COMPANY OPHTAI

Optomed Oyj | March 21, 2022

news image

Optomed and a French artificial intelligence company OphtAI have signed a commercial collaboration agreement, where both parties sell OphtAI artificial intelligence for screening of most common eye diseases together with Optomed Aurora handheld cameras as a complete solution for eye screening. The agreement is focusing mostly on European countries and Canada, where OphtAI has a strong presence. OphtAI offers artificial intelligence for detection of diabetic retinopathy, glaucoma a...

Read More

PHARMA TECH

GOODRX AND MEDIMPACT ANNOUNCE PROGRAM TO ENSURE SEAMLESS ACCESS TO AFFORDABLE PRESCRIPTIONS

Business Wire | September 14, 2023

news image

GoodRx a leading resource for healthcare savings and information, and MedImpact, the independent pharmacy benefit manager (PBM) and health solutions company, announced a new savings solution designed to integrate GoodRx’s prescription pricing in a seamless experience at the pharmacy counter. Now, when an eligible MedImpact member fills a prescription for a generic medication, it will a...

Read More
news image

Pharma Tech

ARMATA PHARMACEUTICALS ANNOUNCES CLEARANCE OF IND FOR PROSTHETIC JOINT INFECTIONS

Armata Pharmaceuticals, Inc | August 02, 2022

Armata Pharmaceuticals, Inc. a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration has cleared Armata's Investigational New Drug application for AP-SA02 in prosthetic joint infection. The company is initiating start-up activities for the Phase 1b/2a trial that will explore the safety, tolerability, and pharmacokinetics of intravenous and i...

Read More
news image

Pharmacy Market

VALEMETOSTAT NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR TREATMENT OF PATIENTS WITH ADULT T-CELL LEUKEMIA/LYMPHOMA

Daiichi Sankyo | December 29, 2021

Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma. ATL is a rare and aggressive type of peripheral T-cell lymphoma that occurs with greater frequency in parts of Japan and other regions.1,2 Patients with ATL face a poor prognosi...

Read More
news image

Business Insights

OPTOMED SIGNS AN INDUSTRIAL PARTNERSHIP WITH A FRENCH AI COMPANY OPHTAI

Optomed Oyj | March 21, 2022

Optomed and a French artificial intelligence company OphtAI have signed a commercial collaboration agreement, where both parties sell OphtAI artificial intelligence for screening of most common eye diseases together with Optomed Aurora handheld cameras as a complete solution for eye screening. The agreement is focusing mostly on European countries and Canada, where OphtAI has a strong presence. OphtAI offers artificial intelligence for detection of diabetic retinopathy, glaucoma a...

Read More
news image

PHARMA TECH

GOODRX AND MEDIMPACT ANNOUNCE PROGRAM TO ENSURE SEAMLESS ACCESS TO AFFORDABLE PRESCRIPTIONS

Business Wire | September 14, 2023

GoodRx a leading resource for healthcare savings and information, and MedImpact, the independent pharmacy benefit manager (PBM) and health solutions company, announced a new savings solution designed to integrate GoodRx’s prescription pricing in a seamless experience at the pharmacy counter. Now, when an eligible MedImpact member fills a prescription for a generic medication, it will a...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us